Transplantation · 1997 · 60 citations · 42 references
PharmacyImmunologyPharmacotherapyImmunotherapyMonoclonal AntibodiesTransplant ImmunologyImmunosuppressionImmunosuppressive TherapyInduction ImmunosuppressionLiver Transplant ImmunosuppressionLiver TransplantationTransplant RejectionAdult Liver TransplantationAntithymocyte Globulin InductionImmunosuppression RegimensLiver Transplant RejectionMonoclonal Antibodies In TransplantationPost-transplant ImmunosuppressionSteroid-resistant RejectionTreatment Of Rejection Episodes
BACKGROUND: Quadruple immunosuppressive induction therapy has been shown to markedly reduce the incidence of acute rejection episodes without increasing the incidence of infectious complications after liver transplantation. However, the use of polyclonal antibody preparations (e.g. antithymocyte globulin [ATG]) is associated with side effects such as fever and tachycardia. To evaluate the efficacy and the safety of a monoclonal antibody directed against the interleukin-2 receptor (BT563) in comparison with ATG as part of a quadruple induction regimen, a prospective, randomized study was conducted. METHODS: Eighty consecutive adult recipients of primary orthotopic liver transplants were randomized to receive either BT563 (10 mg/day; days 0-12; n=39) or ATG (5 mg/kg/day; days 0-6; n=41) in addition to the standard immunosuppressive protocol consisting of cyclosporine, and prednisolone, and azathioprine. RESULTS: Patients treated with BT563 had a significantly lower incidence of steroid-sensitive rejection episodes (3 vs. 11; P<0.025) and also significantly fewer drug-related side effects (4 vs. 18, P<0.038) when compared with patients treated with ATG. The incidence of infectious complications was not different between the two groups. Patient survival did not differ significantly between the two groups (84.6% at 1, 2, and 3 years in the BT563 group and 90.2% at 1 year and 87.8% at 2 and 3 years for the ATG group). Analysis of graft function showed an advantage for the BT563 group in terms of postoperative bilirubin levels. However, no differences were observed in long-term follow-up between the two groups. CONCLUSIONS: Our results indicate that treatment with anti-interleukin-2 receptor antibody as part of quadruple induction therapy after orthotopic liver transplantation is safe and effective and shows fewer steroid-sensitive rejection episodes as well as fewer side effects when compared with quadruple induction therapy including ATG.
42
Lode J. Swinnen, Maria Rosa Costanzo‐Nordin, Susan G. Fisher et al. · New England Journal of Medicine · 1990 · 953 citations
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor
Warren J. Leonard, Joel M. Depper, Gerald R. Crabtree et al. · Nature · 1984 · 857 citations
The IL-2 Receptor β Chain (p70): Role in Mediating Signals for LAK, NK, and Proliferative Activities
Jay P. Siegel, M Sharon, Paula L. Smith et al. · Science · 1987 · 445 citations